Vedolizumab as induction and maintenance therapy for ulcerative colitis.

@article{Feagan2013VedolizumabAI,
  title={Vedolizumab as induction and maintenance therapy for ulcerative colitis.},
  author={Brian G Feagan and P. R. Rutgeerts and Bruce E Sands and S B Hanauer and Jean Fr{\'e}d{\'e}ric Colombel and W J Sandborn and Gert Van Assche and Jeffrey Axler and Hyo-Jong Kim and Silvio Danese and Irving Fox and Catherine Milch and Serap Sankoh and Tim Wyant and Jing Li Xu and Asit Parikh},
  journal={The New England journal of medicine},
  year={2013},
  volume={369 8},
  pages={699-710}
}
BACKGROUND Gut-selective blockade of lymphocyte trafficking by vedolizumab may constitute effective treatment for ulcerative colitis. METHODS We conducted two integrated randomized, double-blind, placebo-controlled trials of vedolizumab in patients with active disease. In the trial of induction therapy, 374 patients (cohort 1) received vedolizumab (at a dose of 300 mg) or placebo intravenously at weeks 0 and 2, and 521 patients (cohort 2) received open-label vedolizumab at weeks 0 and 2, with… CONTINUE READING
Highly Influential
This paper has highly influenced 31 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 364 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 38 references

Antibodies to JC and BK viruses among The New England

  • EA Engels, DE Rollison, P Hartge
  • Journal of Medicine Downloaded from nejm.org at…
  • 2013

Similar Papers

Loading similar papers…